Catch up on stories from the past week (and beyond) at the Slashdot story archive

 



Forgot your password?
typodupeerror
×
Medicine Science Technology

Scientists Develop 10-Minute Universal Cancer Test (theguardian.com) 83

An anonymous reader quotes a report from The Guardian: Scientists have developed a universal cancer test that can detect traces of the disease in a patient's bloodstream. The cheap and simple test uses a color-changing fluid to reveal the presence of malignant cells anywhere in the body and provides results in less than 10 minutes. The test has a sensitivity of about 90%, meaning it would detect about 90 in 100 cases of cancer. It would serve as an initial check for cancer, with doctors following up positive results with more focused investigations. The test was made possible by the Queensland team's discovery that cancer DNA and normal DNA stick to metal surfaces in markedly different ways. This allowed them to develop a test that distinguishes between healthy cells and cancerous ones, even from the tiny traces of DNA that find their way into the bloodstream.

Healthy cells ensure they function properly by patterning their DNA with molecules called methyl groups. These work like volume controls, silencing genes that are not needed and turning up others that are. In cancer cells, this patterning is hijacked so that only genes that help the cancer grow are switched on. While the DNA inside normal cells has methyl groups dotted all over it, the DNA inside cancer cells is largely bare, with methyl groups found only in small clusters at specific locations. Writing in the journal Nature Communications, the Queensland team described a series of tests that confirmed the telltale pattern of methyl groups in breast, prostate and colorectal cancer as well as lymphoma. They then showed that the patterns had a dramatic impact on the DNA's chemistry, making normal and cancer DNA behave very differently in water.
The suspect DNA is added to water containing tiny gold nanoparticles, which turn the water pink. "If DNA from cancer cells is then added, it sticks to the nanoparticles in such a way that the water retains its original color," The Guardian reports. "But if DNA from healthy cells is added, the DNA binds to the particles differently, and turns the water blue."
This discussion has been archived. No new comments can be posted.

Scientists Develop 10-Minute Universal Cancer Test

Comments Filter:
  • Comment removed based on user account deletion
    • That may account for the 10% false reading.

      Although the obvious solution - pun possibly intended - would involve the peptides used to duplicate dna in dna testing.

      The ratios aught to remain the same.

    • by Dunbal ( 464142 ) *
      Biopsy will always be the definitive test. You can see the cancer cells right there in front of you in the microscope. You can determine exactly which type and which stage, as well as appropriate treatments. However a cheap and effective screening test is more than welcome before you start taking a knife/needle to everyone. That way you can divide people into a group that needs further study and a group that doesn't need to be studied for almost no cost. You don't waste time and resources studying false pos
  • not as advertised (Score:2, Interesting)

    by Anonymous Coward

    If you actually read the article, you will notice that assay results of cancerous and non-cancerous samples have a pretty big overlap. This means that there would be many incorrect test results. Also, they mention that not all cancers have the methylation changes necessary that make the assay possible. So, this is another instance of over-broad claims (by the media) as to the research implications.

  • by 140Mandak262Jamuna ( 970587 ) on Thursday December 06, 2018 @10:44PM (#57763978) Journal
    It looks like the false negative rate is 10%. any number on false positives?
  • by movdqa ( 1122661 ) on Thursday December 06, 2018 @11:04PM (#57764038)
    DNA in solid tumors may not migrate into the bloodstream (you actually don't want this as this is how cancer spreads).
    • Cancer cells, being rapidly growing and highly metabolic cells, die relatively often. So there is disproportionately more "circulating tumor DNA" (ctDNA) in the "cell free DNA" (cfDNA) circulating in the blood.

      Now whether that small portion of ctDNA can be detected and characterized, and how reliably that can be accomplished for particular kinds of patients, that is cutting edge cancer research.

      • It may well be possible to detect certain cancers by clever analysis of DNA in the blood. But the changes in DNA are subtle and variable. Just being able to mix it with gold particles and it turn blue sounds like nonsense.

        I have no doubt that some thing was discovered, and it may even relate to cancer, but this summary sound like it has been totally mushed by journalists.

        • by movdqa ( 1122661 )
          Always better to read the actual research paper. You might also have a cancer cell that's fixed by the Mismatch Repair mechanism. Do this report cancer in the case where cells can be repaired?
      • by movdqa ( 1122661 )
        Some cancers have markers on the cell surface and immunotherapy exploits these markers to go after just cancer cells. But some mutations like KRAS, NRAS, HRAS, the so-called undruggables, don't have markers on the cell surface that we currently know of. There has been some remarkable work at NCI, particularly with KRAS G12D and KRAS G12V, that present markers on the cell surface with certain alleles and this has led to a few immunotherapy cures. But this stuff is in its infancy. There are some 39 or so can
    • Cancer spreads by whole cells migrating in the blood stream, not by dna fragments.
  • by Anonymous Coward

    I'm highly skeptical. While cancer does produce hypo-methylated DNA, by the time you can measure it in any significant quantities, the cancer will have already progressed to a very late stage. There are other conditions - including simply aging that can also produce hypo-methylated DNA so that will affect their false positive rate. This seems like the kind of experiment that will not hold up under replication.

  • Badly Oversold (Score:5, Informative)

    by Anonymous Coward on Friday December 07, 2018 @12:34AM (#57764236)

    Disclosure: I'm a cancer biomarker researcher, and these types of studies are my bread & butter. I don't know this group, and they chose to look at tumour types that I'm largely not working on.

    So this study is pretty uninteresting, and is getting a lot of unhelpful media attention. The core observation is that there are differences in methylation in tumour and normal, and that these can be detected in a pretty simple assay (10 min, blah blah). That's all either known, or pretty simple extensions of existing work. Nothing wrong with it, just not hype-worthy.

    Media is then claiming an AUC of ~0.90 (and an operating point with an accuracy of ~85%). The problem is, their test situation is entirely irrelevant. Most of these analyses were based on a comparison of blood from:
    1) healthy age- and sex-matched controls
    2) patients with metastatic disease (cancer that has spread throughout the body)

    This has a litany of problems:
    1) almost all patients are symptomatic pre-metastasis, and thus only a small fraction (~5-25%) of cancers are diagnosed at this stage
    2) patients diagnosed with metastatic disease have often elected to avoid testing (cost, access, personal decision, etc.)
    3) sadly almost all metastatic disease is lethal -- we routinely cure patients with localized disease with surgery or radiotherapy
    4) genomic and epigenomic changes accumulate over time, and metastatic tumours on average have significantly more
    5) there is no health-care economics argument for screening for metastatic disease

    So essentially, the paper says "we can distinguish black from white with 90% accuracy". That's fine, but the media reports are missing the fact that ~95% of real-life cases are gray, and the accuracy of this test will probably be lower in these white vs. gray comparisons. The likelihood is that this "90% accurate test" is actually going to be ~70-80% accurate in real-world settings. Which is fine, but, you know, matches existing cheap diagnostics in most tumour types anyways!

    So in short, this study is over-hyped and goes far to creating a bad culture where people think we are closer to a "cure" than we really are. It's solid science, but in no way worthy of a slashdot article!

    • Too bad all of the best responses to this story are all AC, they should all be ranked higher.

      • There is a serious risk of "astroturfing" both for or against, a testing tool that costs $700 and competes for medical funding with other expensive tools.

        • True, take that post with a grain of salt, but it sure beats the random trolling! At least interesting to hear a possible perspective of the other side of he coin.

    • Agree 100% with parent. I suspect this is a press release generated not-by-the-authors because the research is accepted into a good journal. DNA methylation is old shit (like 30 years). This is a fantastic *experiment* for several reasons: it's got some novelty (different from what the articles are touting), and the experiment is very well designed with positive and negative controls. It takes courage to move outside the mainstream, and it does none of us any service when these results are overhyped.
    • Re:Badly Oversold (Score:5, Insightful)

      by Jay Vickery ( 2908369 ) on Friday December 07, 2018 @02:12AM (#57764398)
      I disagree with you when you say this wasn't worth a slashdot post. It might not be worth it to you but between the summary and your comment I learned something which is why I come here.
      • Re: (Score:2, Informative)

        by Anonymous Coward

        Well, my estimation is that there are probably 10-20 cancer biomarker papers of superior quality published each week. This paper won't be in the top 500 papers in its field this year. I personally believe Slashdot should do better, and highlight high-quality science, not mid-quality work. That of course is just an opinion! :)

    • I suspected that might be the case. What is your preferred approach?

      DNA sequencing is the obvious one, Illumina's next gen sequencers look nice, but processing the data seems slow. You're the expert, I've merely toyed with BLAST and the NCBI toolkit, perused hardware catalogues and salivated over research papers. Yeah, I'm sick.

    • 1) almost all patients are symptomatic pre-metastasis, and thus only a small fraction (~5-25%) of cancers are diagnosed at this stage

      Did you mean 'asymptomatic'?

      • No, symptomatic. Meta-static is the "last" stage of a cancer, where it starts spreading from the original point to other tissues. For instance, you might develop a cancer tumour in your lungs. This will take some time, and you will develop multiple symptoms during this time. After the tumour has progressed past the "fatal" stage it might metastasize, which will cause a tumour to develop in your colon. This "post-fatal" stage is pretty much 100% sure to kill you. What OP was saying was that there are many ma

    • Thanks for the perspective! I was confused about how it would be useful if it only changed color with normal DNA. It seemed like that would require unusual preparation of the suspected cancer to ensure it was not contaminated with non-target DNA.
    • by Artagel ( 114272 )

      I am so glad for your post. I had taken time to look at the publication, and though I am not a researcher, it looked oversold. I also was taken aback when I saw it was with metastatic cancer because the holy grail is early detection, an area I have thought research for early detection has been horrifically underfunded for decades. We spend hundreds of billions on research and treatment of advanced cancers and hardly anything on developing early detection that would greatly reduce the risks to cancer suffere

  • by Anonymous Coward

    hey investors wanna loose another billion? Go for it.

  • Is this going to be another Theranos?
  • Is there an IPO associated with this? Cause it sounds like there's an IPO associated with this...

  • They need to talk about the specificity, not the AUC for a sample that has more instances of cancer than not-cancer. If you use this to screen the general population, the vast majority of whom do not have cancer, the false positives will overwhelm the true positives unless the specificity is very high.

  • Presumably there will always be healthy cells and therefore always some amount of bluing. If possible would you have wanted to leave the water clear for healthy cells and turn blue for malignant ones?

As you will see, I told them, in no uncertain terms, to see Figure one. -- Dave "First Strike" Pare

Working...